BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Staging
44 results:

  • 1. Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.
    Crutcher MM; Snook AE; Waldman SA
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1317-1326. PubMed ID: 36259230
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The complementary role of lymphovascular invasion and perineural invasion in the TNM staging process of rectal cancer.
    Chen T; Wang M; Cheng X; Wang Y; Jiang Y; Fang X; Xiao H
    Medicine (Baltimore); 2022 Sep; 101(39):e30687. PubMed ID: 36181060
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Immunoexpression of TS, p53, COX2, egfr, MSH6 and MLH1 biomarkers and its correlation with degree of differentiation, tumor staging and prognostic factors in colorectal adenocarcinoma: a retrospective longitudinal study.
    Batista WR; Santos G; Vital FMR; Matos D
    Sao Paulo Med J; 2019 May; 137(1):33-38. PubMed ID: 31116268
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Looking back 2018--focused on colorectal cancer].
    Cai J; Wang L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):9-16. PubMed ID: 30703787
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma.
    Usón PLS; Bugano DDG; Moura F; Carvalho RS; Maluf FC
    J BUON; 2018; 23(4):925-935. PubMed ID: 30358195
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Expression of epidermal growth factor receptor (egfr) in colorectal cancer: An immunohistochemical study.
    Ben Brahim E; Ayari I; Jouini R; Atafi S; Koubaa W; Elloumi H; Chadli A
    Arab J Gastroenterol; 2018 Sep; 19(3):121-124. PubMed ID: 30243897
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Analysis of gene expression egfr and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors.
    Carvalho TI; Novais PC; Lizarte FS; Sicchieri RD; Rosa MS; Carvalho CA; Tirapelli DP; Peria FM; Rocha JJ; Féres O
    Acta Cir Bras; 2017 Mar; 32(3):243-250. PubMed ID: 28403349
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in colorectal cancer.
    Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular Biomarkers in the Personalized Treatment of colorectal cancer.
    Sinicrope FA; Okamoto K; Kasi PM; Kawakami H
    Clin Gastroenterol Hepatol; 2016 May; 14(5):651-8. PubMed ID: 26872400
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Relationship between Preoperative ¹⁸F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary colorectal cancer.
    Choi YJ; Kim MJ; Lee BH; Kwon MJ; Hwang HS
    Yonsei Med J; 2016 Jan; 57(1):232-7. PubMed ID: 26632406
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Rectal and colon cancer: Not just a different anatomic site.
    Tamas K; Walenkamp AM; de Vries EG; van Vugt MA; Beets-Tan RG; van Etten B; de Groot DJ; Hospers GA
    Cancer Treat Rev; 2015 Sep; 41(8):671-9. PubMed ID: 26145760
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Biologic therapies in colorectal cancer: indications and contraindications.
    Fakih M
    Am Soc Clin Oncol Educ Book; 2015; ():e197-206. PubMed ID: 25993173
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
    Hur H; Kim NK; Min BS; Baik SH; Lee KY; Koom WS; Ahn JB; Kim H
    Dis Colon Rectum; 2014 May; 57(5):592-601. PubMed ID: 24819099
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
    Etienne-Grimaldi MC; Mahamat A; Chazal M; Laurent-Puig P; Olschwang S; Gaub MP; Formento JL; Formento P; Sudaka A; Boige V; Abderrahim-Ferkoune A; Benchimol D; André T; Houry S; Faucheron JL; Letoublon C; Gilly FN; Delpero JR; Lasser P; Pradere B; Pezet D; Penault-Llorca F; Milano G
    Br J Cancer; 2014 May; 110(11):2728-37. PubMed ID: 24800948
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The role of tumor markers and biomarkers in colorectal cancer.
    Lech G; Slotwinski R; Krasnodebski IW
    Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Proteinuria as a risk factor for mortality in patients with colorectal cancer.
    Kim MJ; Kang YU; Kim CS; Choi JS; Bae EH; Ma SK; Kweon SS; Kim SW
    Yonsei Med J; 2013 Sep; 54(5):1194-201. PubMed ID: 23918569
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
    Garouniatis A; Zizi-Sermpetzoglou A; Rizos S; Kostakis A; Nikiteas N; Papavassiliou AG
    Tumour Biol; 2013 Aug; 34(4):2109-17. PubMed ID: 23580180
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination.
    Viana Lde S; Affonso RJ; Silva SR; Denadai MV; Matos D; Salinas de Souza C; Waisberg J
    Oncology; 2013; 84(2):81-91. PubMed ID: 23128103
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. FAK, CD44v6, c-Met and egfr in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk.
    Garouniatis A; Zizi-Sermpetzoglou A; Rizos S; Kostakis A; Nikiteas N; Papavassiliou AG
    Int J Colorectal Dis; 2013 Jan; 28(1):9-18. PubMed ID: 22733437
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.